NextCure (NXTC) Income from Continuing Operations (2018 - 2026)
NextCure (NXTC) posted Income from Continuing Operations of -$15.1 million for Q2 2026, down 49.04% on a QoQ basis from -$10.1 million in Q1 2026, and up 44.7% year-over-year from -$10.4 million in Q2 2025.
Powered by 
Analysis
NextCure (NXTC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
NextCure has reported Income from Continuing Operations for 9 years, with the latest figure at -$15.1 million in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 44.7% year-over-year to -$15.1 million in Q2 2026; TTM through Jun 2026 was -$43.9 million, a 31.18% increase from a year earlier, with the FY2025 full-year figure at -$57.6 million, up 3.23% from the prior year.
- Income from Continuing Operations was -$15.1 million for Q2 2026 at NextCure, down from -$10.1 million in the prior quarter.
- The five-year high for Income from Continuing Operations was -$8.9 million in Q3 2025, with the low at -$27.3 million in Q2 2025.
- Average Income from Continuing Operations over 5 years is -$15.9 million, with a median of -$15.9 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 66.48% in 2025, then jumped 44.7% in 2026.
- Over 5 years, Income from Continuing Operations stood at -$16.9 million in 2022, then grew by 8.65% to -$15.4 million in 2023, then grew by 18.7% to -$12.5 million in 2024, then climbed by 22.14% to -$9.8 million in 2025, then plunged by 54.77% to -$15.1 million in 2026.
- The last three Income from Continuing Operations figures came in at -$15.1 million (Q2 2026), -$10.1 million (Q1 2026), and -$9.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | NextCure | 37.91 Mn | 37.91 Mn | - | -15.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.10 Mn |
| Mar 31, 2026 | -10.13 Mn |
| Dec 31, 2025 | -9.75 Mn |
| Sep 30, 2025 | -8.92 Mn |
| Jun 30, 2025 | -27.30 Mn |
| Mar 31, 2025 | -11.63 Mn |
| Dec 31, 2024 | -12.53 Mn |
| Sep 30, 2024 | -12.33 Mn |
| Jun 30, 2024 | -16.40 Mn |
| Mar 31, 2024 | -18.26 Mn |
| Dec 31, 2023 | -15.41 Mn |
| Sep 30, 2023 | -15.30 Mn |
| Jun 30, 2023 | -19.28 Mn |
| Mar 31, 2023 | -16.38 Mn |
| Dec 31, 2022 | -16.87 Mn |
| Sep 30, 2022 | -19.30 Mn |
| Jun 30, 2022 | -18.27 Mn |
| Mar 31, 2022 | -22.31 Mn |
| Dec 31, 2021 | -17.61 Mn |
| Sep 30, 2021 | -18.44 Mn |